Vishakhapatnam: AMTZ and its partner Transasia Diagnostics Private Limited, situated at the Andhra Pradesh MedTech Zone (AMTZ), in Vizag city announced a development in diagnostic technology with the launch of the ErbaMDx MonkeyPox RT-PCR Kit. India’s first indigenously developed testing solution for MPox. This innovation signifies a major advancement in the country’s healthcare landscape and epidemic preparedness efforts.
The Kit has achieved rigorous validation from the Indian Council for Medical Research (ICMR) and received emergency authorization from the Central Drugs Standard Control Organisation (CDSCO), under the Ministry of Health and Family Welfare. This validation underscores the kit’s precision and reliability and highlights India’s growing capabilities in critical health diagnostics.
The Kit stands out with its lyophilized components, which enable it to be shipped and stored at ambient temperatures. This feature is particularly vital for regions with limited cold chain infrastructure, ensuring that crucial diagnostic tools are accessible even in the most remote areas. The kit boasts a 12-month shelf life and zero cross-reactivity with other orthopoxviruses, promising exceptional accuracy and dependability.
Dr Jitendra Sharma, MD and Founder CEO of AMTZ, remarked, “the introduction of the ErbaMDx MonkeyPox RT-PCR Kit represents a significant achievement for both AMTZ and the nation. It exemplifies our commitment to advancing healthcare technology and reinforces our role in safeguarding public health against emerging threats.”
The Kit’s launch enhances diagnostic capabilities and reflects India’s position at the forefront of global health innovation. As the nation continues to lead in medical technology advancements, collaborations like those between AMTZ and Transasia Diagnostics are essential in driving future progress and addressing global health challenges.
